Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
Neuroscience|October 19, 2010
Regulation of synaptic strength by sphingosine 1-phosphate in the hippocampusT Kanno, T Nishizaki, R L Proia, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 11, 1994
Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs diseaseS Yamanaka, M D Johnson, A Grinberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 16, 1998
Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedureY Liu, K Suzuki, J D Reed, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 23, 1999
Mice lacking complex gangliosides develop Wallerian degeneration and myelination defectsK A Sheikh, J Sun, Y Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 26, 1999
Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycinM Jeyakumar, T D Butters, M Cortina-Borja, et al.
The Journal of Clinical Investigation|June 13, 1998
Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease miceF Norflus, C J Tifft, M P McDonald, et al.
The Journal of Biological Chemistry|March 21, 1997
Evidence for the involvement of Glu-355 in the catalytic action of human beta-hexosaminidase BM Pennybacker, C G Schuette, B Liessem, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 22, 1997
Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairmentY Liu, A Hoffmann, A Grinberg, et al.
Science (New York, N.Y.)|April 18, 1997
Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycinF M Platt, G R Neises, G Reinkensmeier, et al.
Pageof 6